AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 12, 2026, 8:00 AM ET Kyverna completes BLA submission for miv-cel in stiff person syndrome and reports $41.9 million third quarter 2026 net loss. AI-generated summary · Source: company release
NASDAQ: $KYTXBiotech · Autoimmune cell therapyBLA, cell-therapy safety and dilution risk

KYTX Stock Hub: Kyverna News, Miv-cel and Autoimmune CAR-T

On November 12, 2026, Kyverna announced completion of its rolling SPS BLA, requesting priority review under its RMAT designation; FDA acceptance had not been announced, and a potential launch in 2027 remains subject to approval. KYSA-8 one-year data cover 26 treated patients; gMG longer-term data come from a separate seven-patient Phase 2 cohort. Latest published financials are Q3 2026, with $170.572M September cash and marketable securities. SPS and gMG longer-term data · September 24, 2026 BLA completion and Q3 results · November 12, 2026 Q3 2026 Form 10-Q · November 12 Corporate presentation · October 2026

Last updated: November 12, 2026Market data: November 11, 2026 regular closeFinancial period: September 30, 2026Currency: USD
Research Library · Biotech
Kyverna Therapeutics, Inc. ($KYTX), research updated November 12, 2026
21 pages covering the third-quarter 2026 results and the completed rolling SPS BLA of November 12, the September 30 balance sheet and runway, the KYSA-8 one-year evidence and the gMG Phase 3, the commercial-readiness build, dilution and the Oxford facility, ownership, management and licensing, risks, sources and FAQ. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next catalyst · Announced investor presentation
November 19, 2026 · Jefferies Global Healthcare Conference

Management is scheduled to present in London at 10:00 GMT, equivalent to 05:00 in New York. This is an investor event, without a promise of new clinical data or BLA acceptance. Jefferies conference announcement · November 5, 2026

The November 9 journal publication concerns the earlier KYSA-8 primary analysis; one-year durability was reported in September and presented in October. On November 12, 2026, Kyverna announced completion of the rolling SPS BLA with a request for priority review; FDA acceptance and any PDUFA date had not been announced. BLA completion and Q3 results · November 12, 2026 KYSA-8 publication announcement · November 9, 2026 SPS and gMG longer-term data · September 24, 2026 Corporate presentation · October 2026
KYTX daily price chart
Daily chart · Finviz (affiliate link on click). Explore KYTX on JC Just Charts.

KYTX stock data: financial position and capital

REFERENCE CLOSE
$5.12
November 11 regular session
COMMON-STOCK VALUE
$323.696M
Calculated: $5.12 × 63,221,970 shares (November 6)
CASH + MARKETABLES
$170.572M
September 30 · excludes restricted cash
Q3 NET LOSS
$41.941M
Three months ended September 30
OPERATING CASH USED
$117.270M
Nine months ended September 30
COMMON SHARES
63.222M
November 6 cover-page count
ATM CAPACITY LEFT
$90.7M
September 30 · financing capacity, not cash
TERM LOAN CARRYING
$24.958M
September 30 · $25M nominal principal

At September 30, 2026, resources equal $31.818M cash and equivalents plus $138.754M marketable securities. Restricted cash of $0.551M is separate. Oxford’s up-to-$150M facility had $25M principal drawn; a July 8, 2026 amendment extended availability of the remaining $15M of Term A loans through December 31, 2026, and later tranches have conditions or lender discretion. In Q3 Kyverna sold 733,132 shares under its ATM for $5.330M net. The company expects cash plus amounts available from the amended Oxford facility to provide operating runway into 2028. Q3 2026 Form 10-Q · November 12 BLA completion and Q3 results · November 12, 2026

KYTX stock: durable SPS data with regulatory and treatment risks

Miv-cel is not approved. In KYSA-8, CRS occurred in 24/26 patients, all grade 1 or 2; ICANS occurred in 3/26, all grade 1. Grade 3/4 neutropenia affected five patients, and three had related serious adverse events that resolved. No high-grade CRS or ICANS does not mean no adverse events. Corporate presentation · October 2026

▲ The constructive case

The single-dose SPS study met its primary endpoint and maintained mobility and disability improvements through one year, with 24/26 patients remaining free of chronic SPS immunotherapies. Kyverna announced completion of the SPS BLA on November 12, 2026, requesting priority review. A focused launch strategy and gMG development offer additional paths if regulatory and clinical requirements are met. SPS and gMG longer-term data · September 24, 2026 Corporate presentation · October 2026

▼ The cautious case

KYSA-8 was a 26-patient single-arm study; the gMG Phase 2 cohort had seven patients. Longer observation and controlled confirmation remain important. Cell-therapy logistics, preconditioning, safety, cash consumption and an available ATM all affect the path from promising data to shareholder value. Operating cash use was $117.270M in the first nine months of 2026. Corporate presentation · October 2026 Q3 2026 Form 10-Q · November 12

Latest KYTX news

Nov 12, 2026

Kyverna completes BLA submission for miv-cel in stiff person syndrome; reports Q3 2026 results

Kyverna has completed its rolling BLA submission to the FDA for miv-cel in stiff person syndrome, seeking priority review under RMAT designation. The company reported $170.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, with operating runway expected into 2028. For the third quarter ended September 30, 2026, R&D expenses were $27.0 million, G&A expenses were $15.9 million, and net loss was $41.9 million, or $0.68 per share. Kyverna also elected to deprioritize its KYV-102 program.

Company release · GlobeNewswire
Nov 9, 2026

Kyverna Publishes Registrational Miv-cel Data in Stiff Person Syndrome in JAMA Neurology

Kyverna Therapeutics published the primary analysis of its registrational KYSA-8 trial of miv-cel in stiff person syndrome in JAMA Neurology. The 26 patients received a single dose and showed statistically significant improvements across all primary and secondary endpoints at 16 weeks. Of the 12 patients who required walking aid at baseline, 67% no longer needed walking assistance at 16 weeks. No high-grade CRS or ICANS and no cases of IEC-HS were reported.

Company release · GlobeNewswire

KYTX stock catalysts: rolling BLA, Jefferies and gMG enrollment

The SPS 12-month and gMG longer-term updates were released September 24; October conference presentations and November publication are past. No FDA acceptance or PDUFA date had been announced as of November 12, 2026. Registry phase and enrollment can describe a broader program than an individual published cohort. SPS and gMG longer-term data · September 24, 2026 KYSA-8 publication announcement · November 9, 2026 Kyverna company news

Miv-cel in SPS: one-year durability and the safety denominator

KYSA-8 treated 26 adults in a single-arm study. Median T25FW improvement was 46% at week 16 and 49% at one year. Clinically meaningful improvement occurred in 21/26 and 20/26, respectively; 24/26 remained off chronic immunotherapies at one year. SPS and gMG longer-term data · September 24, 2026 Corporate presentation · October 2026

Grade 3/4 neutropenia occurred in 5/26 and related serious adverse events in 3/26. Low-grade CRS and ICANS occurred despite the absence of high-grade cases. The November publication reports the primary analysis, distinct from the later one-year dataset. Corporate presentation · October 2026 KYSA-8 publication announcement · November 9, 2026

gMG and progressive MS: early cohorts versus confirmation

All seven gMG Phase 2 patients improved meaningfully at week 24; only five had reached at least one year at the June cutoff. Six of seven remained off immunosuppressants at last follow-up. The randomized Phase 3 portion is a separate confirmatory step, with enrollment targeted for mid-2027. SPS and gMG longer-term data · September 24, 2026

The October MS update concerned six treated investigator-study patients, with efficacy available for five. These small, uncontrolled data support further development rather than establish comparative disease modification. Progressive MS investigator-study update · October 23, 2026

Merlintrader Health Score · KYTX

3.25out of 5
Financial position3.0

September 30 cash and marketable securities totaled $170.572M, excluding $0.551M restricted cash; nine-month operating cash use was $117.270M and the Q3 net loss $41.941M. The company forecasts operating runway into 2028, including amounts available from the amended Oxford facility. Q3 2026 Form 10-Q · November 12 BLA completion and Q3 results · November 12, 2026

Catalysts4.0

Kyverna announced completion of the rolling SPS BLA on November 12, 2026, requesting priority review; Jefferies is announced for November 19. gMG Phase 3 enrollment is targeted for mid-2027 and a progressive-MS strategy update for early 2027. Filing, acceptance and approval remain distinct. BLA completion and Q3 results · November 12, 2026 Corporate presentation · October 2026 Jefferies conference announcement · November 5, 2026

Dilution2.5

At September 30, 2026, Kyverna had 9,939,059 options and 2,069,871 unvested RSUs/PRSUs outstanding. The ATM had $90.7M remaining capacity after Q3 sales of 733,132 shares, with $200M unallocated shelf capacity; both can enable future dilution. The $150M Oxford maximum is not cash already received. Q3 2026 Form 10-Q · November 12

Trading liquidity3.0

KYTX trades on Nasdaq with an active daily price history. The latest cover-page common-share count was 63,221,970 on November 6. Regulatory and clinical events can still produce gaps and changes in execution conditions. Q3 2026 Form 10-Q · November 12

Execution3.5

KYSA-8 met its primary endpoint and maintained improvement through one year in 26 treated SPS patients. The study was single-arm, and CRS, low-grade ICANS and severe neutropenia occurred. gMG confirmation and commercial execution remain ahead. SPS and gMG longer-term data · September 24, 2026 Corporate presentation · October 2026

Weighted calculation: 3.0 × 30% + 4.0 × 30% + 2.5 × 20% + 3.0 × 10% + 3.5 × 10% = 3.25 out of 5. Editorial assessment dated November 12, 2026, reassessed the same day after the BLA completion and Q3 results: scores unchanged, because lower September cash remains within the company’s runway guidance into 2028 and BLA completion was the Q4 milestone already reflected in the catalyst score. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of approval.

KYTX red flags

KYTX Stock FAQ: Kyverna Questions Answered

What is the next KYTX stock catalyst for Kyverna?

As of November 12, 2026, Kyverna’s next announced investor event is Jefferies on November 19 at 10:00 GMT / 05:00 New York. Kyverna announced completion of the rolling SPS BLA on November 12, 2026; FDA acceptance and any PDUFA date had not been announced. BLA completion and Q3 results · November 12, 2026 Jefferies conference announcement · November 5, 2026 Corporate presentation · October 2026

Is Kyverna miv-cel FDA-approved, and does KYTX have a PDUFA date?

As of November 12, 2026, miv-cel remains investigational. That day Kyverna announced completion of its rolling SPS BLA, requesting priority review under its RMAT designation; it had not announced FDA acceptance or a PDUFA date. RMAT designation and a request for priority review do not constitute approval. BLA completion and Q3 results · November 12, 2026 Corporate presentation · October 2026 Kyverna company news

How much cash does Kyverna have for KYTX development?

At September 30, 2026, Kyverna had $170.572M in cash, equivalents and marketable securities, excluding $0.551M restricted cash, after $117.270M of operating cash use in nine months. Its forecast operating runway into 2028 includes amounts available from the amended Oxford loan facility; it is not a guarantee based solely on the cash balance. Q3 2026 Form 10-Q · November 12 BLA completion and Q3 results · November 12, 2026

What are the main KYTX share dilution risks for Kyverna holders?

At September 30, 2026, Kyverna had 9,939,059 options and 2,069,871 unvested RSUs/PRSUs besides ordinary shares; 63,221,970 common shares were outstanding on November 6. In Q3 it sold 733,132 shares under its ATM for $5.330M net, leaving $90.7M of ATM capacity, with another $200M unallocated under the shelf. Registered financing capacity is not cash received. Q3 2026 Form 10-Q · November 12

What are the latest Kyverna earnings for KYTX stock?

Kyverna reported Q3 2026 results on November 12, 2026: R&D expenses of $27.0M, G&A expenses of $15.9M and a net loss of $41.941M, or $0.68 per share, with $170.572M of cash and marketable securities at September 30 and $117.270M of operating cash use in the first nine months. BLA completion and Q3 results · November 12, 2026 Q3 2026 Form 10-Q · November 12

What does Kyverna Therapeutics do with miv-cel for KYTX?

As of November 12, 2026, Kyverna develops miv-cel, an autologous CD19 CAR-T therapy for B-cell-driven autoimmune diseases. Its prioritized neurologic programs include stiff person syndrome, generalized myasthenia gravis and progressive multiple sclerosis. Miv-cel is intended as a single infusion after preconditioning and remains investigational. On November 12, 2026, Kyverna said it had deprioritized its KYV-102 program to focus on its late-stage miv-cel indications. Corporate presentation · October 2026

What did Kyverna report for KYTX miv-cel in stiff person syndrome?

On September 24, 2026, Kyverna reported one-year data in 26 treated KYSA-8 patients, including 49% median T25FW improvement and 92% remaining free of chronic SPS immunotherapies. The study was single-arm. The November 9 publication concerns the earlier primary analysis, not a new randomized dataset. SPS and gMG longer-term data · September 24, 2026 KYSA-8 publication announcement · November 9, 2026

What are the clinical safety risks of Kyverna miv-cel for KYTX?

In the October 2026 presentation, KYSA-8 safety included CRS in 24/26 patients and ICANS in 3/26, all low grade. Five had grade 3/4 neutropenia and three had related serious adverse events that resolved. The absence of high-grade CRS or ICANS does not eliminate other risks. Corporate presentation · October 2026

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $KYTX or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

Trending now

Passenger aircraft and winter holiday luggage illustrate the comparison of American, Delta, United and Southwest.
American $AAL $DAL $UAL $LUV: Holiday Airline Test
Bright illustration of blood cells, medicines and molecular structures for hereditary angioedema research.
BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices
Colorful minerals and processing infrastructure illustrating rare-earth co-product economics.
Ramaco $METC $AREC $NB $UUUU: Rare Earth Economics
Colorful semiconductor memory stack and inspection equipment illustrating the AI memory supply chain.
Micron $MU, $RMBS, $AMKR, $CAMT: AI Memory Economics